id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
2420178,211e55f3-0237-4a52-996a-01bcb856593c,1T,"BOCKORNY GROUP, INC.",289773,ALLIANCE FOR CELL THERAPY NOW,2020,first_quarter,MED,"Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of FY2020","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,1,2020-02-10T11:48:08.740000-05:00
2420288,4999592f-19c5-4277-90d6-ae33c5a0aa9a,Q1,D.L. GARDNER AND ASSOCIATES,401105409,CIPLA USA,2020,first_quarter,MED,funding for infectious disease research,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",12500,,0,0,2020-03-17T06:13:14.023000-04:00
2420290,bdb90fc0-5066-4c24-96f7-e6fa75fa3c19,1T,D.L. GARDNER AND ASSOCIATES,401105409,CIPLA USA,2020,first_quarter,MED,funding for infectious disease research,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",12500,,0,1,2020-03-17T06:21:21.280000-04:00
2420510,125ca5c2-f65a-4a08-8f6c-c2e4a1511304,Q1,"FRANCIS EDWARD & CRONIN, INC.",311314,CURE ALZHEIMER'S FUND,2020,first_quarter,MED,Issues and legislation related to Alzheimer's disease research,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",20000,,0,0,2020-04-01T10:08:32.540000-04:00
2420511,33e8293b-a123-47e2-8522-b6387dbb91dd,Q1,"FRANCIS EDWARD & CRONIN, INC.",311314,"PATH DECISION SUPPORT SOFTWARE, LLC",2020,first_quarter,MED,Issues and legislation related to diabetes treatment and diagnosis,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,0,2020-04-01T10:11:33.253000-04:00
2420552,7ec9c022-a5a5-48ea-8f5b-be35876d8cd7,Q1,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2020,first_quarter,MED,Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,144981,0,0,2020-04-01T12:27:56.353000-04:00
2420794,87c27416-c4fd-4633-9658-7e4a21f463a9,Q1,MARSHALL BRACHMAN,6848,BAYLOR SCOTT AND WHITE HEALTH -- FORMERLY BAYLOR HEALTH CARE SYSTEM,2020,first_quarter,MED,support funding for medical research programs,"HOUSE OF REPRESENTATIVES,SENATE",33000,,0,0,2020-04-02T15:34:40.220000-04:00
2420961,7a78f251-8bc6-4b9d-9493-c6f060cda578,Q1,"FEDERAL SOLUTIONS, LLC",311371,MISSISSIPPI STATE UNIVERSITY,2020,first_quarter,MED,Labor/HHS/Education Appropriations: Provisions relating to disease research.,"Education, Dept of,HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Oceanic & Atmospheric Administration (NOAA),SENATE",50000,,0,0,2020-04-03T13:53:45.383000-04:00
2421087,284498c9-3bcb-4a4f-8823-2786ba17ab32,Q1,ATLAS ADVOCACY,401100069,BLADDER CANCER ADVOCACY NETWORK,2020,first_quarter,MED,CDMRP; Disease Awreness resolution,"HOUSE OF REPRESENTATIVES,SENATE",9000,,0,0,2020-04-03T17:07:24.797000-04:00
2421218,d142503b-d20c-4576-8de0-704c4f8eed55,Q1,"AUBURN HEALTH STRATEGIES, LLC",292697,"NEUROTECH, LLC",2020,first_quarter,MED,EEG monitoring,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-05T19:30:22.247000-04:00
2421231,c0b5c184-b17e-4df3-a2c5-62ad40daa681,Q1,ACUITY STRATEGIC PARTNERS LLC,401105363,"AMICUS THERAPEUTICS, INC.",2020,first_quarter,MED,Reimbursement for rare disease patient care,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-06T08:44:46.997000-04:00
2421236,3a73a81e-c109-4e0e-8b8d-c4afd336f90a,Q1,COMMONWEALTH POLICY SOLUTIONS,401105004,RARE ACCESS ACTION PROJECT,2020,first_quarter,MED,Reimbursement for rare disease patient care,"HOUSE OF REPRESENTATIVES,SENATE",12000,,0,0,2020-04-06T08:48:48.217000-04:00
2421237,f9aa73d5-cc71-44dc-857f-91d24dccbf17,Q1,COMMONWEALTH POLICY SOLUTIONS,401105004,TRISALUS LIFE SCIENCES,2020,first_quarter,MED,"Medical device development for oncology, drug delivery for oncology","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-06T08:49:49.423000-04:00
2421351,b77b75f7-eda5-42d7-8192-a563cac59a99,Q1,SQUIRE PATTON BOGGS,30906,UNIVERSITY OF GEORGIA,2020,first_quarter,MED,"Traumatic brain injury research, funding, and outreach opportunities. Research related to emerging and infectious diseases.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-06T11:45:46.573000-04:00
2421368,39f411ed-bdad-4afd-b854-d93bcebca3e9,Q1,"RICHARD J. SCHOLZ, P.A. (FKA JACOBS SCHOLZ & WYLER, LLC)",400361684,PPLA,2020,first_quarter,MED,Pharmaceutical labeling,Food & Drug Administration (FDA),18700,,0,0,2020-04-06T12:56:03.200000-04:00
2421692,9729928d-f9de-42e2-a9ad-ab1b08370cfb,1T,"MANATT, PHELPS, AND PHILLIPS",23645,"SCIENCE CARE, INC.",2020,first_quarter,MED,H.R. 1835 Consensual Donation and Research Integrity Act of 2019,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,1,2020-04-07T13:15:12.867000-04:00
2421702,8cc05251-61d9-4df5-99d1-3a2ea45adc44,Q1,SQUIRE PATTON BOGGS,30906,"IMPACT JOURNALS, LLC",2020,first_quarter,MED,National Library of Medicine indexing matters.,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-07T13:34:28.923000-04:00
2421786,0d915b6d-1336-4a22-b8bb-f2ce479887fd,Q1,SQUIRE PATTON BOGGS,30906,ALLIANCE FOR BIOSECURITY,2020,first_quarter,MED,Preparedness and response as it relates to Biosecurity.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",100000,,0,0,2020-04-07T14:19:19.907000-04:00
2421812,46e92b70-ee68-41cb-a069-ecb5e1c2b270,Q1,SQUIRE PATTON BOGGS,30906,NATIONAL CANNABIS ROUNDTABLE,2020,first_quarter,MED,"Reforming federal law and policy governing medical research, financial transactions, and tax deductions applicable to cannabis and allowing states and territories to set and enforce their own laws governing cannabis use.","HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,White House Office",120000,,0,0,2020-04-07T14:34:38.610000-04:00
2421993,51f19d84-0b6f-4b5b-8d24-7f1c487b5ca4,Q1,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),1466,ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE (FORMERLY AACC),2020,first_quarter,MED,"On February 28, 2020 AACC wrote to the Food and Drug Administration requesting that the agency permit laboratories develop laboratory developed tests to detect COVID-19 without having to obtain an Emergency Use Authorization from the agency.

On March 25, 2020 AACC wrote to the Department of Health and Human Services requesting that pathologists and related staff be permitted to work offside during the COVID-19 pandemic under their existing CLIA lab certificate.

On March 27, 2020 AACC endorsed S.3512, the Verified Innovative Testing in American Laboratories (VITAL) Act, which would codify federal regulation of laboratory developed tests under the Clinical Laboratory Improvement Amendment regulations overseen by the Centers for Medicare and Medicaid Services.","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2020-04-08T10:55:21.433000-04:00
2422294,df6ffb09-b5a1-45d8-8328-914de327965d,Q1,WAKE FOREST UNIVERSITY HEALTH SCIENCES,6781,WAKE FOREST UNIVERSITY HEALTH SCIENCES,2020,first_quarter,MED,FY21 Department of Labor/HHS Appropriations bill,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,150000,0,0,2020-04-09T09:42:12.707000-04:00
2422400,3a43f7fb-44d6-4177-847b-c00164406d1d,Q1,"UPSTREAM CONSULTING, INC.",88278,RARE ACCESS ACTION PROJECT,2020,first_quarter,MED,Reimbursement coverage by Medicaid and Medicare for rare disease therapies.,"HOUSE OF REPRESENTATIVES,SENATE",8000,,0,0,2020-04-09T11:59:40.340000-04:00
2423344,e52e60eb-5e80-4f0c-912b-eac314b25b0a,Q1,"CASSIDY & ASSOCIATES, INC.",8453,"ONE HEALTH SOLUTIONS, LLC",2020,first_quarter,MED,"HR 6074 Coronavirus Preparedness and Response Supplemental Appropriations Act
 
HR 6201 Families First Coronavirus Response Act
 
HR 748 CARES Act
 
Telehealth Issues","Agriculture, Dept of (USDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,U.S. Agency for International Development (USAID)",60000,,0,0,2020-04-10T23:52:30.190000-04:00
2423414,6255e1be-ca8b-4b8d-9333-051088e2d213,Q1,"REPUBLIC CONSULTING, LLC",401016871,IQVIA,2020,first_quarter,MED,Monitor Data and Science policy.,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-11T14:13:24.893000-04:00
2423694,59af1f17-835c-43b7-b04a-1f979eee0e65,Q1,"K&L GATES, LLP",32098,NATIONAL ASSN FOR BIOMEDICAL RESEARCH,2020,first_quarter,MED,Issues related to medical research (no legislation).,"HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT)",20000,,0,0,2020-04-13T10:51:13.457000-04:00
2423874,54b70154-3cfa-48df-bd68-cbfd992efe63,Q1,GREEN PLAINS INC.,401104765,GREEN PLAINS,2020,first_quarter,MED,"Issues related to the Novel Coronavirus and the disease COVID-19; Issues related to the production of industrial grade alcohol for inclusion in hand sanitizer; Issues related to the transportation and tax treatment for industrial grade alcohol for inclusion in hand sanitizer; H.R. 748, the CARES Act","Agriculture, Dept of (USDA),Commerce, Dept of (DOC),Energy, Dept of,Environmental Protection Agency (EPA),Federal Emergency Management Agency (FEMA),Federal Motor Carrier Safety Administration,Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE,Transportation, Dept of (DOT),Treasury, Dept of,U.S. Trade Representative (USTR),White House Office",,190000,0,0,2020-04-13T12:11:47.367000-04:00
2424198,0e4617d7-3799-4e39-908b-d8495f2970ea,Q1,RAY C CULVER III,11468,ARKANSAS CHILDREN'S HOSPITAL,2020,first_quarter,MED,Funding for USDA ARS Human Nutrition Research Centers in the FY2021 House and Senate Agricultural Appropriations bills,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-13T15:30:43.300000-04:00
2424460,6152dfe2-42eb-415a-a881-3099d6e74fb9,Q1,KUTAK ROCK LLP,21962,NE ENTERPRISES,2020,first_quarter,MED,Reauthorization of Pandemic and All Hazards Preparedness Act and related matters,,20000,,0,0,2020-04-13T18:01:00.427000-04:00
2424497,95ab2487-2887-4dd1-842b-f20cca7f0ec9,Q1,"THE PETRIZZO GROUP, INC.",305932,CEL-SCI CORPORATION,2020,first_quarter,MED,"Activity related to phase III clinical trial in head and neck cancer to boost the immune system before the ravages of surgery, radiation and chemotherapy. The Phase III trial is the largest ever in head and neck cancer with 928 patients enrolled.","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2020-04-13T20:28:09.953000-04:00
2424507,82584681-b9cc-4370-b2e4-3b984dd26757,Q1,"THE PETRIZZO GROUP, INC.",305932,ALLEN INSTITUTE,2020,first_quarter,MED,"Advocated for funding of the BRAIN Initiative, Alzheimer's research full funding for NIH. Advocated for the development of open data hosting, and integrated, scalable data analysis hubs for the BRAIN Initiative at NIH. The Human Projectome Project, a comprehensive Atlas of cell types in human brain and the Mouse Connectome Project for BRAIN Initiative","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",50000,,0,0,2020-04-13T22:02:12.590000-04:00
2424571,a8458d84-4311-44d2-a53b-94eb5524e2fa,Q1,AMERICAN SOCIETY OF ADDICTION MEDICINE,401104864,AMERICAN SOCIETY OF ADDICTION MEDICINE,2020,first_quarter,MED,"Advocated for FY2021 Labor HHS Appropriations bill - appropriations related to strengthening the addiction services workforce, including full funding of the loan repayment program for the substance use disorder treatment workforce authorized in the SUPPORT Act, increase in funding for the mental and substance use disorders training demonstration program authorized in 21st Century Cures Act, funding for preventive medicine residency programs, and $8.8 billion for discretionary Health Resources and Services Administration programs.

Supported HR 3414 (and prior versions)/ S. 2892 - Opioid Workforce Act of 2019 - bill increases the number of residency positions eligible for graduate medical education payments under Medicare for hospitals that have addiction or pain management programs, with an aggregate increase of 1,000 positions over a five-year period.

Supported HR 3165 and S 1737 - Mental Health Parity Compliance Act - strengthen parity in mental health and substance use disorder benefits.  Advocated for its inclusion in the Lower Health Care Costs Act of 2019.

Supported S 873 and HR 1879 - Stabilize Medicaid and CHIP Coverage Act which would provide for 12 months of continuous enrollment in Medicaid and CHIP to ensure better access to care and reduce churn.  This bill is not specific to mental health, but it would provide significant stability to those patients and providers. 

Supported H.R.1920 - Medicaid Bump Act - To amend title XIX of the Social Security Act to provide a higher Federal matching rate for increased expenditures under Medicaid for mental and behavioral health services, and for other purposes.

Supported H.R.1329 - Medicaid Reentry Act - This bill allows Medicaid payment for medical services furnished to an incarcerated individual during the 30-day period preceding the individual's release.

Supported S 824/HR 1767 - Excellence in Mental Health and Addiction Treatment Expansion Act This legislation would extend and expand the Certified Community Behavioral Health Clinic (CCBHC) demonstration, which is set to end in mid-2019. 

Supported the Parity Enforcement Act (HR 2848). This legislation would give the U.S. Department of Labor authority to levy civil monetary penalties against health insurers and plan sponsors for parity violations of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008.


Supported S.1012/ HR 2062 Protecting Jessica Grubbs Legacy Act/ Overdose Prevention and Patient Safety Act to amend the Public Health Service Act to protect the confidentiality of substance use disorder patient records.

Supported HR 4974:  the MATE Act - to amend the Controlled Substances Act to require physicians and other prescribers of controlled substances to complete training on treating and managing patients with opioid and other substance use disorders (which shall also satisfy certain training required to receive a waiver for dispensing narcotic drugs for maintenance or detoxification treatment),and for other purposes.

Supported a conditional endorsement of The Mainstreaming Addiction Treatment Act, which is contingent upon the elimination of DEA regulations on medications in Schedules III-V that are based on the prescribing intent to treat addiction and a requirement that all DEA controlled substance prescribers complete medical education on addiction. 

Supported the Humane Correctional Health Care Act , H.R. 4141/S. 2305, which would repeal the Medicaid Inmate Exclusion. The exclusion strips health coverage from Medicaid enrollees who are involved in the criminal justice system. 

Supported H.R. 3925, the Reducing Barriers to Substance Use Treatment Act, introduced by Representatives Paul Tonko (D-NY) and David McKinley (R-VA). The bill would prohibit state Medicaid programs, beginning in October 1, 2020, and ending September 30, 2025, from imposing prior authorizations or other types of utilization control policies or procedures on medications approved to treat OUD, including, with respect to the provision of those medications, counseling services and behavioral therapy. 

Supported the Reversing the Youth Tobacco Epidemic Act of 2019 (HR 2339) which would, among other things, amend the Federal Food, Drug, and Cosmetic Act with respect to the sale and marketing of tobacco products 

Supported HR 4742, Protecting American Lungs Act, a bill to impose a tax on nicotine used in e-cigarettes.

Supported HR 5632, The FDA Accountability for Public Safety Act, which would require the FDA Commissioner to make the final decision on drug approvals if the advisory committee advises against approval, among other things. 

Advocated for the addiction of a Medicaid Provider Status requirement on any new State Opioid Response Grant funding

Advocated for the use of audio-visual telehealth for initation of new OTP patients to be treated with methadone

Advocated for an increase in the DATA 2000 waiver patient limit

Advocated for telehealth buprenorphine initiation as an exception to Ryan Haight

Advocated for addiction CMS guidance and coverage related to telehealth

Advocated to allow Opioid Treatment Programs (OTPs) to operate mobile units without requiring them to obtain a separate registration as well as more flexibility regarding take-home medications dispensed from an OTP

Advocated for $38.5B in emergency relief funds for mental health disorder and addiction treatment providers as a result of losses suffered due to COVID-19

Advocated for inclusion of provisions in HR 748 of the CARES Act, related to the Opioid Workforce Act, the Reducing Barriers to Substance Use Disorder Treatment, Medicaid Reentry, emergency health care provider relief funds, reform of 42 CFR Part 2, amont other ASAM priorities","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,80000,0,0,2020-04-14T06:57:26.107000-04:00
2424598,8086c06c-242a-4680-b5d6-1b85ac656e81,Q1,HACKENSACK MERIDIAN HEALTH,401104109,HACKENSACK MERIDIAN HEALTH,2020,first_quarter,MED,"National Institutes of Health funding 
Behavioral health 
Substance abuse, opioids, and patient data","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2020-04-14T07:54:32.923000-04:00
2424633,ec7c5e25-98ed-435c-b7da-5376ef4b8ea9,Q1,MUNK POLICY & LAW,401105075,SOUTHERN METHODIST UNIVERSITY,2020,first_quarter,MED,Traumatic Brain Injury Research,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-14T09:36:52.007000-04:00
2424876,319cb952-e09b-4b32-ad3a-0e2f786dcf10,Q1,MCDERMOTT+ LLC,401103287,COALITION FOR 21ST CENTURY MEDICINE,2020,first_quarter,MED,Issues concerning regulation of laboratory-developed tests.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",40000,,0,0,2020-04-14T11:50:48.610000-04:00
2424951,43a8d74e-2b36-48d1-82cf-f52d9a5fe37c,Q1,ISEMAN & ASSOCIATES LLC,401103582,"TICHENOR VENTURES, LLC",2020,first_quarter,MED,Monitoring biotech legislation,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-04-14T12:30:12.947000-04:00
2424969,9abad2a2-99b4-41ec-9218-709b8359f5c8,1T,ISEMAN & ASSOCIATES LLC,401103582,"PILLNURSE, LLC",2020,first_quarter,MED,Medical device funding,"HOUSE OF REPRESENTATIVES,SENATE",22500,,0,1,2020-04-14T12:40:19.193000-04:00
2425169,3788506a-9cd6-4a02-ade7-208748d201b0,Q1,SQUIRE PATTON BOGGS,30906,"LA MAESTRA FOUNDATION ON BEHALF OF LA MAESTRA FAMILY CLINIC, INC.",2020,first_quarter,MED,Health care public policy and regulatory advocacy matters,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-14T15:08:27.297000-04:00
2425323,fd3dcc33-0efd-4a0a-93f1-e53de890c714,Q1,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,401103437,AMERICAN SOCIETY FOR DERMATOLOGIC SURGERY ASSOCIATION,2020,first_quarter,MED,"HR 1379
IT Strategic Health Plan","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES",,,0,0,2020-04-14T16:15:14.947000-04:00
2425385,884035c9-e6b5-460c-8658-91f18b3433ab,Q1,BLUEBIRD STRATEGIES,401105447,"MYRIAD GENETICS, INC.",2020,first_quarter,MED,Legislation to regulate clinical labs under CLIA and FDA.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-14T16:44:38.050000-04:00
2425392,4aebdff9-846e-49a5-af65-defab58de0f8,Q1,BLUEBIRD STRATEGIES,401105447,MYOTONIC,2020,first_quarter,MED,Increasing funding for Myotonic Dystrophy research. Fiscal year 2020 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.,"Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-14T16:48:39.983000-04:00
2425502,ae132bae-6d19-4651-8571-a9c575bc9b9b,Q1,"THE PETRIZZO GROUP, INC.",305932,OMEROS CORPORATION,2020,first_quarter,MED,Advocated for Medicare Part B packaged payment reforms; and the expansion of the non-opioid pain management drug exclusion to the drugs functioning as supplies during a surgical procedure packaging policy.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",80000,,0,0,2020-04-14T23:54:26.040000-04:00
2425503,796a730c-4333-4c85-9fc1-b427731e3389,Q1,"THE PETRIZZO GROUP, INC.",305932,SEATTLE CHILDREN'S HOSPITAL RESEARCH AND FOUNDATION,2020,first_quarter,MED,"Funding for NIH research; H.R. 4159, PACT Act.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2020-04-15T00:00:26.713000-04:00
2425527,f6cb1bc2-062d-425e-bad5-d0652de9aa28,Q1,AMERICAN PHYSICAL THERAPY ASSOCIATION,3093,AMERICAN PHYSICAL THERAPY ASSOCIATION,2020,first_quarter,MED,"NIH Rehab issues
APTA role with NIH
Traumatic brain injury research
Support of work done at CDC Injury Center on elder adult falls, TBI, youth sports concussions
NIH Research and Development funding
Physical Therapist role in childhood obesity
Relocate TBI State Grant Program to ACL
NIDILRR - Rehab research
Nomination to NIH Committees
Safety of Children in School (Restraint & Seclusion)
Falls and Falls Prevention","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Small Business Administration (SBA),Social Security Administration (SSA),Veterans Affairs, Dept of (VA),White House Office",,271987,0,0,2020-04-15T08:26:36.737000-04:00
2425550,844b7db2-cf6b-463d-a6a7-cc67b9ac4bbd,Q1,THOMPSON ADVISORY GROUP,319610,SONNET BIOTHERAPEUTICS,2020,first_quarter,MED,medical research,SENATE,20000,,0,0,2020-04-15T09:03:45.093000-04:00
2425681,fc2631c7-35d7-4441-afba-14a7fff76984,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,HEREDITARY HEMORRHAGIC TELANGIECTASIA FOUNDATION,2020,first_quarter,MED,"Research Opportunities at the Department of Defense, the National Institutes of Health, and the Centers for Disease Control and Prevention
FY21 Defense Appropriations Act, DoD research on vascular malformations
FY21 Labor-HHS-Education Act, NIH and CDC research on HHT","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2020-04-15T10:14:27.073000-04:00
2425690,e22213ab-ef89-435c-b737-3435d7115f34,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,PANCREATIC CANCER ACTION NETWORK (PANCAN),2020,first_quarter,MED,"cancer research at DOD and NIH
HR 2968; S 2474 Department of Defense Appropriations Act 2020, pancreatic cancer research
HR 1158, Consolidated Appropriations Act, DoD medical research funding for pancreatic cancer
HR 2740, Labor, HHS, Education, Defense, State, Foreign Operations & Energy & Water 
HR 1865, Further Consolidated Appropriations Act, NIH funding for pancreatic cancer research 
Development Appropriations Act 2020, NIH research in pancreatic cancer
Peer Reviewed Medical Research","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",40000,,0,0,2020-04-15T10:17:30.293000-04:00
2425692,ab030690-10de-4861-b778-2a3a522594a4,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,FOUNDATION FOR PERIPHERAL NEUROPATHY,2020,first_quarter,MED,"FY21 Defense Appropriations Act, DoD funding for peripheral neuropathy research","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-15T10:21:31.600000-04:00
2425740,8699bf0e-92c1-4607-a192-e1648ba773c3,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,TUBEROUS SCLEROSIS ALLIANCE,2020,first_quarter,MED,"FY21 Defense Appropriations Act, Tuberous Sclerosis Complex Research Program
FY21 Labor-HHS-Appropriations Act, NIH and CDC research on tuberous sclerosis complex
NIH research on tuberous sclerosis complex","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2020-04-15T10:36:44.070000-04:00
2425787,3da02cc2-0847-499a-8134-07f3469affbe,Q1,"EFB ADVOCACY, LLC",401104430,UNITED FOR MEDICAL RESEARCH,2020,first_quarter,MED,Funding Issues Related to the National Institutes of Health,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-15T10:47:59.287000-04:00
2425978,ccd67d05-0828-4819-9414-80b21e1f4d7c,Q1,GIBBONS P.C.,89873,BERGEN ANESTHESIA GROUP P.C.,2020,first_quarter,MED,Seeking amendments to Surprise Medical Billing Legislation.,"HOUSE OF REPRESENTATIVES,SENATE,White House Office",40000,,0,0,2020-04-15T11:52:08.697000-04:00
2426132,968bf36f-e38e-4918-a9a4-36277166828e,Q1,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,DEFENSE HEALTH RESEARCH CONSORTIUM,2020,first_quarter,MED,"Y21 Defense Appropriations Act, Defense Health Research Programs
FY21 National Defense Authorization Act, Defense Health Research Programs","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-15T12:26:57.013000-04:00
2426194,d1708ab9-08fe-4f99-8a74-4399557f9a9c,Q1,"GOVERNMENT COUNSEL, LLC",401105070,"HOOPER,LUNDY& BOOKMAN, PC (OBO ROCHE DIAGNOSTICS)",2020,first_quarter,MED,H.R.6102 & S.3404-Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-15T12:44:14.467000-04:00
2426257,1d0f8bbb-2474-4024-bd04-b7c5b59a78c8,Q1,WATKINS & EAGER PLLC,401104403,NATIONAL FRAGILE X FOUNDATION,2020,first_quarter,MED,Work to assist in developing a legislative strategy for funding for training & development for Fragile X clinicians & other medical providers.  Encourage Members to act favorably on matters of interest related to funding & research.,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-04-15T12:58:33.417000-04:00
2426849,5c91df18-1a90-4094-9331-e193116bd6c7,Q1,MANATOS & MANATOS,23634,BARBARA ANN KARMANOS CANCER INSTITUTE,2020,first_quarter,MED,PPS-exempt cancer hospitals,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-15T15:49:20.200000-04:00
2427067,281648fd-82e4-47d5-922d-de34eb453af2,Q1,"MEHLMAN CONSULTING, INC.",284950,AEGIS SCIENCES CORPORATION,2020,first_quarter,MED,"H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136; Provisions related to coverage of diagnostic testing","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-15T17:22:22.667000-04:00
2427145,debbdcf6-9708-4026-b0e3-a4ef4905ebee,1@,"BOCKORNY GROUP, INC.",289773,ALLIANCE FOR CELL THERAPY NOW,2020,first_quarter,MED,"Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of FY2020","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,1,2020-04-15T18:00:50.843000-04:00
2427251,f3ceb225-c616-43ba-8c20-627057d3273e,1T,THE WATTS GROUP PLLC,401105118,NOVARTIS,2020,first_quarter,MED,Gene therapy innovation,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,1,2020-04-15T23:21:20.163000-04:00
2427497,7e0fd076-e271-4082-b3e5-da2626da6471,1T,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2020,first_quarter,MED,"Hemophilia research, prevention, surveillance and service programs and issues","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,1,2020-04-16T09:50:28.300000-04:00
2427529,827811d9-41a5-4d80-b3cc-c4bd38949810,1T,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2020,first_quarter,MED,Research and public health programs in epilepsy.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,1,2020-04-16T09:56:37.020000-04:00
2427661,8145cf3e-3a5a-447b-b9cb-8394d0ac872f,1A,"CONGRESSIONAL SOLUTIONS, INC (CSI)",297237,UNIVERSITY OF NORTH TEXAS SYSTEM,2020,first_quarter,MED,COVID19 Research,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2020-04-16T10:40:07.897000-04:00
2427672,763b69fc-45b6-47bd-8410-23df7e4ed0b5,Q1,FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC),86196,COLOR HEALTH (FKA COLOR GENOMICS),2020,first_quarter,MED,Lobbying related to healthcare issues.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-16T10:43:09.630000-04:00
2427679,2b09f41d-c6f6-41b7-a507-0cc476c2ea34,Q1,"THE CONAFAY GROUP, LLC",401004840,"HAWAII BIOTECH, INC.",2020,first_quarter,MED,Medical countermeasures.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-16T10:49:24.987000-04:00
2427746,6a5aaf40-f1b5-46b0-b4ba-93e5314088a4,Q1,O'NEILL AND ASSOCIATES,73134,"POINT32HEALTH SERVICES, INC. (FORMERLY TUFTS HEALTH PLAN)",2020,first_quarter,MED,Medical,"HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2020-04-16T11:07:43.480000-04:00
2427758,5accf944-29c1-4787-bebe-39b1c3365597,1T,"THE CONAFAY GROUP, LLC",401004840,"XERIS PHARMACEUTICALS, INC.",2020,first_quarter,MED,Biomedical research issues,HOUSE OF REPRESENTATIVES,10000,,0,1,2020-04-16T11:10:47.700000-04:00
2427814,cbb1cf71-e6f3-4feb-bafb-578d47b3f31b,Q1,O'NEILL AND ASSOCIATES,73134,ANALOGIC,2020,first_quarter,MED,Medical Technology,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2020-04-16T11:19:01.963000-04:00
2427821,b8a040ae-1e36-48d9-80d1-13b16c1b195f,Q1,FGS GLOBAL (US) LLC (FKA FGH HOLDINGS LLC),86196,"INTUITIVE SURGICAL, INC.",2020,first_quarter,MED,Lobbying related to health care issues.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-16T11:20:03.567000-04:00
2427831,ec049d68-7cf6-4fad-a7bd-792180252a0e,Q1,LNE GROUP,308811,HOSPICE OF THE WESTERN RESERVE,2020,first_quarter,MED,lobbied for medical issues,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",,,0,0,2020-04-16T11:22:06.233000-04:00
2427841,f1191b7b-8d42-4382-b013-5ea2b22f5d4b,Q1,LNE GROUP,308811,OHIOGUIDESTONE (FORMALLY KNOWN AS GUIDESTONE),2020,first_quarter,MED,lobbied for medical issues,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-16T11:23:08.090000-04:00
2427919,7d09cf44-21de-4b96-93ea-3206df18979c,Q1,"THE CONAFAY GROUP, LLC",401004840,EMERGEX VACCINES HOLDING LTD.,2020,first_quarter,MED,Influenza and respiratory disease research,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-16T11:34:25.910000-04:00
2427978,fcf842d3-1a6d-40ea-80ba-b1211f1c91df,Q1,LNE GROUP,308811,UNIVERSITY HOSPITALS HEALTH SYSTEM,2020,first_quarter,MED,lobbied for medical issues,"Bureau of Industry and Security (BIS),Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-16T11:45:45.937000-04:00
2428199,145219e7-67cb-4b12-ace1-5fffca36990c,Q1,THE JACKSON LABORATORY,401104723,THE JACKSON LABORATORY,2020,first_quarter,MED,"Issues pertaining to basic science research and biomedical research.
The background and use of animal models in biomedical research.
National Institutes of Health and the Federal Bureau of Investigation scrutinizing researchers with global research collaborations. 
Issues pertaining to COVID-19 diagnosis and model discovery.","HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT)",,30000,0,0,2020-04-16T12:16:29.277000-04:00
2428354,25f8fd43-b423-4d44-bd3c-fdcca8e7fcf3,Q1,"GREENBERG TRAURIG, LLP",16896,AMERICAN SOCIETY INTERVENTIONAL PAIN PHYSICIANS,2020,first_quarter,MED,"Outreach and monitoring related to the implementation of the Patient Protection and Affordable Care Act (P.L. 111-148).
Outreach and monitoring related to federal and legislative activity related to health care and reauthorization of National All Schedules Prescription Electronic Reporting Act (NASPER) (P.L. 109-60). 
Outreach and monitoring related to federal and legislative activity related to Medicare Reimbursement and Medicare Advantage Reimbursement.
Outreach and monitoring related to federal issues and legislation associated with health care policy.
Outreach and monitoring related to federal issues and legislation associated with opioids.
Outreach and monitoring related to Tricare reimbursement
H.R. 3107 Improving Seniors Timely Access to Care Act of 2019",SENATE,30000,,0,0,2020-04-16T12:48:08.867000-04:00
2428385,f73f469e-c459-46f2-8f49-168f482bf527,Q1,STANFORD UNIVERSITY,36492,STANFORD UNIVERSITY,2020,first_quarter,MED,"HR6074
Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020

HR6201 
Families First Coronavirus Response Act of 2020

HR748 
Coronavirus Aid Relief and Economic Security Act of 2020 

Health Professions Programs

Graduate Medical Education Funding

Pediatric GME Programs","Energy, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE,State, Dept of (DOS)",,90000,0,0,2020-04-16T12:54:17.447000-04:00
2428440,d0074289-5471-4dc6-9b74-829cade4bd18,Q1,SQUIRE PATTON BOGGS,30906,THOMAS JEFFERSON UNIVERSITY,2020,first_quarter,MED,"Advancing health system legislative and regulatory issues including: the development of a collaborative, interdisciplinary translational cancer research program; develop the Partners in Innovation, Education, and Research (PIER) program.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2020-04-16T13:05:32.380000-04:00
2428929,7d6e0416-bc09-4311-b9cf-606b536db2b6,Q1,INFECTIOUS DISEASES SOCIETY OF AMERICA,54836,INFECTIOUS DISEASES SOCIETY OF AMERICA,2020,first_quarter,MED,"Medical liability; antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants.","Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,90000,0,0,2020-04-16T14:48:09.497000-04:00
2429026,786c19a1-a277-4fae-8c2d-9ec3640890ee,Q1,NATIONAL MULTIPLE SCLEROSIS SOCIETY,69674,NATIONAL MULTIPLE SCLEROSIS SOCIETY,2020,first_quarter,MED,N/A,"HOUSE OF REPRESENTATIVES,SENATE",,132919,0,0,2020-04-16T15:05:34.130000-04:00
2429255,9068b786-79d6-448c-9361-91c7968fb382,Q1,"THE CONAFAY GROUP, LLC",401004840,"PREACTIVE TECHNOLOGIES, INC.",2020,first_quarter,MED,Traumatic Brain Injury Prevention,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-16T16:12:44.697000-04:00
2429276,d4e1b866-4565-4499-87f4-24a1cb4bed12,Q1,"THE CONAFAY GROUP, LLC",401004840,PHLOW CORPORATION,2020,first_quarter,MED,US pharmaceutical manufacturing,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-16T16:21:50.700000-04:00
2429352,c9fe9621-38d8-45c4-aa8b-4490e164f6e5,Q1,"THE CONAFAY GROUP, LLC",401004840,ACADIA PHARMACEUTICALS INC.,2020,first_quarter,MED,Pharmaceutical research.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-16T16:50:11.507000-04:00
2429458,dd08857e-de3a-4704-9aa2-143da22d6b4c,Q1,"THE CONAFAY GROUP, LLC",401004840,"CIDARA THERAPEUTICS, INC.",2020,first_quarter,MED,Support for research on viral diseases,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-16T17:14:36.237000-04:00
2429718,01658314-a9df-48ec-9bf0-a5ad0e893b44,1T,FAEGRE BAKER DANIELS CONSULTING,34158,GLOBAL DOWN SYNDROME FOUNDATION,2020,first_quarter,MED,Fiscal Year 2021 Labor HHS appropriations for Down Syndrome Research; NIH research funding,"HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",,,0,1,2020-04-16T19:30:57.277000-04:00
2429903,7b954993-6bfb-4409-85cf-2152fd90cf22,Q1,VAN SCOYOC ASSOCIATES,39837,"ARUP LABORATORIES, INC.",2020,first_quarter,MED,"H.R.6102, Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2020, Diagnostic Lab Testing




COVID-19 Laboratory Testing related issues, as follows:

Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, FY2020 

Public Law 116-127, Families First Coronavirus Response Act

Public Law 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-17T06:07:49.727000-04:00
2429909,4a523543-dd1a-44da-9635-7ea1d1d974bb,Q1,VAN SCOYOC ASSOCIATES,39837,MEDICAL COLLEGE OF WISCONSIN,2020,first_quarter,MED,"Healthcare research and development related issues, as follows:

Energy and Water Development and Related Agencies Appropriations Act, FY2021

Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, FY2021

Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, FY2021","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-17T06:10:50.967000-04:00
2429981,fa9514ec-268b-4f4b-9c67-28933614748f,Q1,VAN SCOYOC ASSOCIATES,39837,MEDICAL UNIVERSITY HOSPITAL AUTHORITY,2020,first_quarter,MED,"Medical research and development related issues:

National Institutes of Health, and various institutes and bureaus thereof

Health Resources Services Administration","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2020-04-17T07:13:09.483000-04:00
2430092,b50f210f-06db-499a-9949-66c5c5cf23a1,Q1,VAN SCOYOC ASSOCIATES,39837,GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION,2020,first_quarter,MED,"CDC, Infectious Diseases

Research Centers in Minority Institutions

E-Cigarettes related issues

Public Law 116-123, Coronavirus Preparedness and Response Supplemental Appropriations Act, FY2020, Higher Education research related issues; and SARS-CoV2 issues

Public Law 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act, Higher Education research related issues; and SARS-CoV2 issues



Monitor the following:

Agency for Healthcare Research and Quality

Medicaid Disparities NIH

Public Health","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-17T08:02:31.727000-04:00
2430116,c400832a-00a9-4857-be63-58b44c600609,Q1,"CAPITOL DECISIONS, INC.",55165,VAN SCOYOC ASSOCIATES (MEDICAL UNIVERSITY HOSPITAL AUTHORITY),2020,first_quarter,MED,"Medical reseerach and development related isssues

National Institutes of Health, and various institutes and bureaus thereof

Health Resources Services Administration","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2020-04-17T08:15:34.047000-04:00
2430360,0f0f76d4-f7fe-493e-8d05-6e238dd14a8c,Q1,BRACEWELL LLP,6837,NATIONAL BRAIN TUMOR SOCIETY,2020,first_quarter,MED,work related to the advancement of the Cancer Drug Coverage Parity Act and PCHETA (H.R. 647); Peer-review cancer research; Drug pricing and shortages; COVID-19 Response Issues,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2020-04-17T10:00:30.027000-04:00
2430363,eb7a3e9d-8fe1-4bc3-b3b8-a697b50fe4bb,1T,GOLDBUG STRATEGIES LLC,400701094,"23ANDME, INC.",2020,first_quarter,MED,"in vitro diagnostics, clinical laboratories, digital health regulation",Food & Drug Administration (FDA),,,0,1,2020-04-17T10:00:30.593000-04:00
2430432,5bc22f55-3bbd-4f05-a665-dd87d512dbb2,Q1,WINNING STRATEGIES WASHINGTON,50796,I AM ALS,2020,first_quarter,MED,Funding for ALS research in annual Defense and Labor-HHS-Education appropriations bills,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",20000,,0,0,2020-04-17T10:14:48.727000-04:00
2430499,92344024-7f13-47b5-95cb-dbfb0850ab00,Q1,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2020,first_quarter,MED,"Support for federal agencies that fund medical and disease research 
Support for increased federal funding for research and response efforts in response to COVID-19","Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE",,70000,0,0,2020-04-17T10:23:06.180000-04:00
2430595,9a43106d-4222-43d2-9146-5c563683b1b9,Q1,GOLDBUG STRATEGIES LLC,400701094,COALITION FOR 21ST CENTURY MEDICINE,2020,first_quarter,MED,"in vitro diagnostics, clinical laboratories, digital health regulation","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",19500,,0,0,2020-04-17T10:35:24.453000-04:00
2430652,45c5153b-427c-496d-a3d3-f16ecb58a517,Q1,WINNING STRATEGIES WASHINGTON,50796,PHLOW CORPORATION,2020,first_quarter,MED,Domestic manufacturing of essential generic medicines; supply chain disruptions and shortages of foreign manufactured medicines,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-17T10:43:36.113000-04:00
2430749,2c782acb-940a-480f-8fc5-7ca433670f82,Q1,MCDERMOTT WILL & SCHULTE LLP,24338,MAYO CLINIC,2020,first_quarter,MED,Issues impacting academic medical centers.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2020-04-17T10:55:55.773000-04:00
2430776,f4b4e056-680a-4b62-934a-f75a522e7ad5,Q1,WINNING STRATEGIES WASHINGTON,50796,RETRACTABLE TECHNOLOGIES INC (RTI),2020,first_quarter,MED,Response to COVID-19,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2020-04-17T11:04:06.210000-04:00
2430785,d598c5c8-1a4a-488d-ad14-ca68b9656a67,Q1,"OAK RIDGE ASSOCIATED UNIVERSITIES, INC.",401104196,"OAK RIDGE ASSOCIATED UNIVERSITIES, INC.",2020,first_quarter,MED,"NIH funding for aging science, tobacco and peer review activities","Defense, Dept of (DOD),Energy, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2020-04-17T11:04:07.350000-04:00
2431224,59351be5-0e57-4200-8244-535f5dcc6a49,Q1,MUTUAL OF OMAHA,26284,MUTUAL OF OMAHA,2020,first_quarter,MED,"HR 5826; Consumer Protection Against Surprise Medical Bills Act.  Several proposals were introduced this Congress to address surprise billing: H.R. 861 - End Surprise Billing Act 2019; H.R. 3502-Protecting People From Surprise Medical Billing Act; H.R. 3630 - No Surprise Act; H.R. 4223 - Protecting Patients from Surprise Medical Bills; S. 1266 - Protecting Patients from Surprise Medical Bills Act; S. 1531, Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; and S. 1895 - Lower Health Care Costs Act.  This legislation, with H.R. 5800 - Ban Surprise Billing Act, received more traction and establishes a process for arbitration.

HR 5800; Ban Surprise Billing Act.  Several proposals were introduced this Congress to address surprise billing: H.R. 861 - End Surprise Billing Act 2019; H.R. 3502-Protecting People From Surprise Medical Billing Act; H.R. 3630 - No Surprise Act; H.R. 4223 - Protecting Patients from Surprise Medical Bills; S. 1266 - Protecting Patients from Surprise Medical Bills Act; S. 1531, Stopping the Outrageous Practice of Surprise Medical Bills Act of 2019; and S. 1895 - Lower Health Care Costs Act.  This legislation, with H.R. 5826 - Consumer Protection Against Surprise Medical Bills Act, would use a market-based benchmark of the local median in-network rate for amounts less than or equal to $750 and allows providers and payers to elect an arbitration process for any amounts for which the median in-network rate is above that threshold.","HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2020-04-17T11:50:42.490000-04:00
2431249,5fb8e525-37b6-4464-9862-1549f2ddab20,Q1,"WILLIAMS AND JENSEN, PLLC",41454,GLOBAL DOWN SYNDROME FOUNDATION,2020,first_quarter,MED,Support for down syndrome research funding.,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office",40000,,0,0,2020-04-17T11:54:47.037000-04:00
2431394,d6b2c39c-4367-4012-820f-490b113b1ab3,Q1,FAEGRE DRINKER BIDDLE & REATH LLP,12631,DRUGS FOR NEGLECTED DISEASES INITIATIVE OF NORTH AMERICA,2020,first_quarter,MED,Issues related to anti-microbial resistance and neglected tropical diseases.,,10000,,0,0,2020-04-17T12:14:24.143000-04:00
2431742,0951fdd4-815e-486e-aaa8-d113b8dc5cc5,Q1,THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH,314055,THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH,2020,first_quarter,MED,"Support for Medical Research Funding Programs at the National Institutes of Health, the National Eye Institute, and the Department of Defense","HOUSE OF REPRESENTATIVES,SENATE",,65583,0,0,2020-04-17T12:58:01.760000-04:00
2431792,4f1da57a-bb66-4faa-9828-597be39adf0a,Q1,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,400271247,MASSACHUSETTS BIOTECHNOLOGY COUNCIL,2020,first_quarter,MED,Meetings regarding proposed changes to Medicare Part B and Medicare Part D reimbursement that negatively impact patient access to innovative therapies.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Patent & Trademark Office (PTO),SENATE",,25000,0,0,2020-04-17T13:12:15.377000-04:00